A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

Stopped Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.

Conditions

• Alzheimer Disease

Interventions

• DRUG: REM0046127 High Dose
• DRUG: REM0046127 Low Dose
• DRUG: Placebo

Sponsor

reMYND